Skip to main content
. 2022 Feb 15;57(4):633–640. doi: 10.1038/s41409-022-01592-y

Fig. 2.

Fig. 2

Cumulative incidence of t-MDS/t-AML, non-myeloid second primary malignancy (“other second malignancy”) and death before any second primary malignancy after salvage auto-HCT performed with remobilized stem cells. Numbers below the graph indicate the number of patients at risk.